Skip to main content

ICU Sedation

5
Pipeline Programs
4
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
3
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Pfizer
PRECEDEXApproved
dexmedetomidine hydrochloride
Pfizer
injection1999

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
1
Dexmedetomidine hydrochloridePhase 31 trial
Active Trials
NCT02757625Completed63Est. May 2017
Orion
OrionUK - Cambridge
1 program
1
DexmedetomidinePhase 4
Orion Pharma
Orion PharmaUK - Reading
1 program
1
DexmedetomidinePhase 41 trial
Active Trials
NCT03813277Completed60Est. May 2018
Maruishi Pharmaceutical
1 program
1
Dexmedetomidine hydrochloridePhase 3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orion PharmaDexmedetomidine
PfizerDexmedetomidine hydrochloride

Clinical Trials (2)

Total enrollment: 123 patients across 2 trials

Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU

Start: Mar 2017Est. completion: May 201860 patients
Phase 4Completed
NCT02757625PfizerDexmedetomidine hydrochloride

Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit

Start: Jul 2016Est. completion: May 201763 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.